2STEIN M E, BEN-SCHACHER M, KUTON A, et al. Primary lymphoma of the liver: clinical features and outcome of 9 patients[J]. J BUON, 2005, 10 (4) : 505- 509. 被引量：1
3NASR BEN AMMAR C, CHAARI N, KOCHBATI L, et al. Primary non-Hodgkin lymphoma of the liver: case re-port and review of the literature [ J ]. Cancer Radiother (法文), 2006, 10 (8): 595-601. 被引量：1
4GZUZMAN M S,GRILLO-LOPEZ A J,WHITE C A,et al.Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric-anti-CD20 monoclonal antibody and CHOP chemotherapy[J].J Clin Oncol,1999,17(1):268-276. 被引量：1
5MARTINELLI G,LASZLO D,FERRERI A J,et al.Clinical activity of rituximab in gastricmargimal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter Pylori therapy[J].J Clin Oncol,2005,23(9):1979-1983. 被引量：1
6Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin, 1998, 48 ( 1 ): 6-29. 被引量：1
7Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20 ) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 2001,97 (5): 1392-1398. 被引量：1
8Vose JM, Link BK, Grossbard ML, et al. Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma. J Clin Oncol, 2001, 15, 19 (2):389-397. 被引量：1
9Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J, 2001,2 (6): 378-384. 被引量：1
10Fisher R I,Gaynor E R,Dahlberg S,et al.Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J].N Engl J Med,1993,328(14):1002-1006. 被引量：1
